Here's a summary of Sai Parenterals Limited's investor presentation, focusing on key insights for retail investors: **1. Business Performance:** Sai Parenterals has seen robust growth, with consolidated revenue jumping significantly. The CDMO (Contract Development and Manufacturing Organization) segment, driven by long-term contracts, has been a key growth driver. Exports have...
**Sai Parenterals: Q4 & FY26 Performance and Growth Strategy** Sai Parenterals has posted strong results, with FY26 consolidated revenue at ₹381 Cr. Standalone performance was impressive, with revenue, EBITDA, and PAT growing 31%, 23%, and 64% YoY, respectively, driven by robust CDMO momentum. CDMO revenue saw a remarkable surge of...
